The Nevada-focused gold miner said Thursday it plans to offer $250 million of convertible senior notes due 2031, or up to $287.5 million if an option granted to initial purchasers to buy additional ...

Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior Unsecured Notes due March 1, 2031, issued under Rule 144A to bolster its funding ...

Nebius Group (NBIS) announced on Wednesday that it has priced an upsized, $4B private offering of convertible senior notes. Shares were fractionally higher in premarket trading. The $4B note offering ...

CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount ...

I-80 Gold is selling $200 million of convertible bonds to help advance the miner's five gold projects, refurbish a processing plant and fund the expansion of its resource base. The Nevada-focused gold ...

Ormat Technologies (ORA) is raising up to $975.7M through private convertible notes due 2031, including $725M in 1.50% Series A notes and $150M in 0% Series B notes, up from its earlier $750M plan, ...

Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced ...

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due ...

"We are extremely pleased with the outstanding response to the Convertible Note Offering from high quality institutional investors in the United States, which is a tremendous endorsement of Caledonia ...

$1.0 billion offering of 0.25% convertible senior notes due 2032 $1.0 billion offering of 1.00% convertible senior notes due 2033 $300 million greenshoe fully exercised Capped call transactions ...